ReviewIs lipid signaling through cannabinoid 2 receptors part of a protective system?
Introduction
The mammalian body has a highly developed immune system, whose main role is to guard against protein attack and prevent, reduce or repair a possible injury. It is inconceivable that through evolution analogous biological protective systems have not been developed against non-protein attacks. Are there mechanisms through which our body lowers the damage caused by various types of neuronal as well as non-neuronal insults? The answer is of course positive. Through evolution numerous protective mechanisms have been evolved to prevent and limit tissue injury.
We believe that lipid signaling through cannabinoid 2 (CB2) receptors is a part of such a protective machinery and CB2 receptor stimulation leads mostly to sequences of activities of a protective nature. Inflammation/tissue injury triggers rapid elevations in local endocannabinoid levels, which in turn regulate fast signaling responses in immune and other cells modulating their critical functions. Endocannabinoids and endocannabinoid-like molecules acting through the CB2 cannabinoid receptor have been reported to affect a large number of pathological conditions, ranging from cardiovascular [1], [2], gastrointestinal [3], [4], liver [5], [6], [7], kidney [8], [9], lung [10], neurodegenerative [11], [12], [13], [14] and psychiatric [15], [16], [17], [18], [19], [20] disorders to pain [21], [22], cancer [23], [24], [25], [26], bone [27], [28], reproductive system [29], [30], [31] and skin pathologies [32] (Fig. 1). This receptor works in conjunction with the immune system and with various other physiological systems. As numerous excellent reviews have been published on the actions of the endocannabinoid system on specific topics, in this Review we aim to summarize some of the protective actions of the CB2 receptor stimulation with endocannabinoids or synthetic agonists, and the possibly biological mechanisms involved in these effects. While CB2 receptor activation in general mediates immunosuppressive effects, which limit inflammation and associated tissue injury in large number of pathological conditions, in some disease states activation of the CB2 receptor may enhance or even trigger tissue damage, which will also be discussed alongside the protective actions.
Section snippets
The endocannabinoid system and endocannabinoids
The endocannabinoid system is a latecomer to the family of neuromodulators. Looking back, its late discovery was an anomaly. Despite the advances made in the chemistry of cannabinoids, the molecular basis of cannabinoid activity remained enigmatic for several decades. The chemistry of the constituents of the cannabis plant was investigated from the mid 19th century intermittently for almost a century [33], but the main psychoactive constituent, Δ9-tetrahydrocannabinol (THC), was isolated in
CB2 receptors and endocannabinoids in health and disease
The CB2 receptor was previously considered to be expressed predominantly in immune and hematopoietic cells. Indeed, CB2 receptors are expressed in almost all human peripheral blood immune cells with the following rank order of mRNA levels: B cells > NK cells > monocytes > PMNs > T cells, respectively (overviewed in [76]). The CB receptor expression in immune cells can be influenced by various inflammatory, e.g. bacterial lipopolysaccharide (LPS), and other triggers activating these cells, and may
Effects of CB2 receptor modulation in disease states
The significance of CB2 receptor activation in the above mentioned immunomodulatory effects of endocannabinoids and of various cannabinergic ligands is now becoming increasingly recognized, and most likely these effects are largely responsible for the anti-inflammatory properties of endogenous or synthetic ligands observed in a multitude of disparate diseases and pathological conditions, ranging from atherosclerosis, myocardial infarction, stroke, inflammatory pain, gastrointestinal
Conclusions
Overwhelming evidence has established an important role for endocannabinoid-CB2 receptor signaling in a large number of the major pathologies affecting humans. The broad spectrum of actions that can be attributed to CB2 receptor signaling in inflammatory, autoimmune, cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric and many other diseases have been reviewed here in some detail (Fig. 1 and Table 2). Most likely, the primary cellular targets and executors of the CB2
Acknowledgements
This study was supported by the Intramural Research Program of NIH/NIAAA (to P.P.) and by NIDA grant #9789 (to R.M.). The authors are indebted to Dr. George Kunos for providing key resources and support and apologize to colleagues whose important work could not be cited because of the size limitations of this review.
References (286)
- et al.
Cannabinoids in intestinal inflammation and cancer
Pharmacol Res
(2009) - et al.
Cannabinoids and the gut: new developments and emerging concepts
Pharmacol Ther
(2010) - et al.
Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy
Free Radic Biol Med
(2010) - et al.
The endocannabinoid system in targeting inflammatory neurodegenerative diseases
Trends Pharmacol Sci
(2007) - et al.
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Trends Pharmacol Sci
(2007) - et al.
Brain cannabinoid CB2 receptor in schizophrenia
Biol Psychiatry
(2010) - et al.
The effects of the cannabinoid CB2 receptor antagonist, AM630, on isolation rearing – induced behavioural deficits in rats
Schizophr Res
(2010) - et al.
Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833
Pain
(2009) - et al.
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
Brain Res Rev
(2009) - et al.
Endocannabinoid system modulation in cancer biology and therapy
Pharmacol Res
(2009)
Endocannabinoids: friends and foes of reproduction
Prog Lipid Res
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
Trends Pharmacol Sci
A historical overview of chemical research on cannabinoids
Chem Phys Lipids
Receptors for acylethanolamides-GPR55 and GPR119
Prostaglandins Other Lipid Mediat
Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling
J Biol Chem
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
Biochem Pharmacol
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain
Biochem Biophys Res Commun
Biology of endocannabinoid synthesis system
Prostaglandins Other Lipid Mediat
The enzymatic inactivation of the fatty acid amide class of signaling lipids
Chem Phys Lipids
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2
Eur J Med Chem
Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors
Bioorg Med Chem Lett
Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands
Bioorg Med Chem Lett
Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern
Bioorg Med Chem Lett
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy
Neuropharmacology
Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization
Blood
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity
J Am Coll Cardiol
Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart
Life Sci
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
Gastroenterology
Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis
Gastroenterology
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations
Hypertension
The emerging role of the endocannabinoid system in cardiovascular disease
Semin Immunopathol
Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver
Am J Physiol Gastrointest Liver Physiol
CB2 receptors as new therapeutic targets for liver diseases
Br J Pharmacol
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases
Am J Physiol Gastrointest Liver Physiol
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model
Br J Pharmacol
The endocannabinoid system as an emerging target of pharmacotherapy
Pharmacol Rev
CB2 receptors in the brain: role in central immune function
Br J Pharmacol
The endocannabinoid system as a target for the treatment of motor dysfunction
Br J Pharmacol
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression
Ann NY Acad Sci
Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors
Br J Pharmacol
Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice
J Psychopharmacol
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain
Br J Pharmacol
Cannabinoids: potential anticancer agents
Nat Rev Cancer
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas
Glia
Targeting the endocannabinoid system for the treatment of cancer – a practical view
Curr Top Med Chem
Cannabinoid receptors and the regulation of bone mass
Br J Pharmacol
Cannabinoids and the skeleton: from marijuana to reversal of bone loss
Ann Med
CB2 receptors in reproduction
Br J Pharmacol
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis
Proc Natl Acad Sci USA
Isolation, structure and partial synthesis of an active constituent of hashish
J Am Chem Soc
Cited by (353)
The role of transient receptor potential vanilloid 1 (TRPV1), a modulator of the endocannabinoid system in anxiety, depression, and cocaine addiction
2023, Neurobiology and Physiology of the Endocannabinoid SystemMedical cannabis and use in migraine
2023, Medicinal Usage of Cannabis and CannabinoidsNonneurological aspects of the endocannabinoid system: Nonalcoholic fatty liver disease
2023, Neurobiology and Physiology of the Endocannabinoid SystemTargeting the CB (2) receptor to delay progression of cardiovascular diseases
2023, Medicinal Usage of Cannabis and CannabinoidsEndocannabinoid System and the Otolaryngologist
2022, Otolaryngologic Clinics of North America